During the 90. a lot of work was done in this direction particularly in the pharmaceutical, biotech, and environmental industry. Unfortunately, at that time we only had silica Type A (different types of silanol groups). We also worked with PS/DVB but could not get high ligand density. After 2000 MS moved into the pharmaceutical industry and the focus on ligand-target molecules disappeared. After 2010 the hedge fund moved into the health sector and outsourced research to the universities. Unfortunately, Academia and Industry were preoccupied with reinventing nanotechnology and not with creating new selection/extraction tools. Recently we established a new compact chromatography system tool to continue developing affinity ligand based separation/purification strategies. In order to help you, we need to know what you mean as Cell partners? (Type of molecules and molecular weight) If you have confidentiality problems please continue your communication through the contact page at www.chromatographyshop.com. Do you have access to surface measuring technology e.g. TOF SIMS?

Dear,

Thank for your answer. We have formulated hypothesis for drug/cell partners interaction. They could be unfolded protein response (UPR) or Glucose-regulated Protein 78 kDa (GRP78, also known as BiP). May be, It could be tubulin and in the worst case, for us little RNA such as tyrosyl-tRNA.

We have plate-form for Mass Spectrometry, i will ask to engineers if they have TOF SIMS or related.

Thanks for the support@Willi_Glettig